Feb 1, 2019Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018Operating profit increased by 6% measured in local currencies when adjusted for the cost of severance and the priority review voucher for oral semaglutide
Nov 1, 2018Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018Adjusting for severance costs related to lay-offs in the third quarter of 2018, operating profit increased by 4% in local currencies.
- Oct 22, 2018Saxenda® is the first and only FDA-approved medicine in a pen indicated to help adults lose weight and keep it off
Visit the download center to download Novo Nordisk video and more
Sign up to receive our new alerts